CN118340760A - OPO structural fat for preventing or improving intestinal epithelial barrier injury and application thereof - Google Patents
OPO structural fat for preventing or improving intestinal epithelial barrier injury and application thereof Download PDFInfo
- Publication number
- CN118340760A CN118340760A CN202410500133.9A CN202410500133A CN118340760A CN 118340760 A CN118340760 A CN 118340760A CN 202410500133 A CN202410500133 A CN 202410500133A CN 118340760 A CN118340760 A CN 118340760A
- Authority
- CN
- China
- Prior art keywords
- epithelial barrier
- opo
- intestinal
- intestinal epithelial
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000006378 damage Effects 0.000 title claims abstract description 38
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 25
- 208000014674 injury Diseases 0.000 title claims abstract description 25
- 210000005026 intestinal epithelial barrier Anatomy 0.000 title claims abstract description 25
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 150000002632 lipids Chemical class 0.000 claims abstract description 15
- 230000000968 intestinal effect Effects 0.000 claims abstract description 13
- 230000004890 epithelial barrier function Effects 0.000 claims abstract description 12
- 210000004082 barrier epithelial cell Anatomy 0.000 claims abstract description 11
- 102000004162 Claudin-1 Human genes 0.000 claims abstract description 10
- 108090000600 Claudin-1 Proteins 0.000 claims abstract description 10
- 210000000130 stem cell Anatomy 0.000 claims abstract description 10
- 230000006907 apoptotic process Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 210000002175 goblet cell Anatomy 0.000 claims abstract description 8
- 108090000304 Occludin Proteins 0.000 claims abstract description 7
- 102000003940 Occludin Human genes 0.000 claims abstract description 7
- 230000035755 proliferation Effects 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 7
- 108010063954 Mucins Proteins 0.000 claims abstract description 6
- 102000015728 Mucins Human genes 0.000 claims abstract description 6
- 230000028327 secretion Effects 0.000 claims abstract description 6
- 235000013376 functional food Nutrition 0.000 claims description 9
- 230000000112 colonic effect Effects 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000002029 Claudin Human genes 0.000 claims description 5
- 108050009302 Claudin Proteins 0.000 claims description 5
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 5
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229940051875 mucins Drugs 0.000 claims description 3
- 210000004922 colonic epithelial cell Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 abstract description 24
- 210000002919 epithelial cell Anatomy 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 13
- 238000012360 testing method Methods 0.000 description 7
- 229920003045 dextran sodium sulfate Polymers 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 230000007413 intestinal health Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000019737 Animal fat Nutrition 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 101100096703 Drosophila melanogaster mtSSB gene Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- GQZXNSPRSGFJLY-UHFFFAOYSA-N hydroxyphosphanone Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to application of OPO structural fat in preparing a medicament for preventing or improving intestinal epithelial barrier injury. The invention discovers that OPO structural lipid can inhibit apoptosis of colon epithelial cells by promoting proliferation of intestinal stem progenitor cells and secretion of mucin of goblet cells and increasing expression of ZO-1, occludin and Claudin-1 proteins, thereby improving damage of colon epithelial barrier.
Description
Technical Field
The invention relates to the field of medicines, in particular to an application of OPO structural fat in preventing or improving intestinal epithelial barrier injury.
Background
At present, the intestinal health of the national is not optimistic. According to incomplete statistics, 90% of people in China have intestinal health problems of different degrees. The intestinal epithelial barrier is an important barrier for maintaining homeostasis in the body as a "goalkeeper" for intestinal health, and once the barrier function is disrupted, toxins, harmful bacteria and harmful substances in the intestinal tract will enter the blood circulation system, causing autoimmune diseases and even a variety of diseases of the central nervous system. Thus, improving intestinal epithelial barrier function is critical to promote intestinal health and an increase in overall health levels.
The structure of triglycerides has a significant impact on intestinal health. The sn-2 palmitate is used as functional structural fat and is rich in animal fat such as breast milk fat, lard and the like. Studies have shown that milk fat with high sn-2 palmitate can increase intestinal beneficial bacteria, alleviate colon pathological lesions, and improve intestinal inflammation. The sn-2 palmitate exists in various forms, wherein the 1, 3-dioleate-2-palmitate triglyceride (OPO structural fat) is the most main type, and has the physiological functions of promoting the absorption of fatty acid and calcium of infants, promoting bone development, improving intestinal flora, improving constipation and the like. There is currently no report on the prevention or improvement of intestinal epithelial barrier injury by OPO structural lipids.
Disclosure of Invention
In order to solve the technical problems, the invention comprises the following aspects:
in a first aspect the present invention provides the use of an OPO structured lipid in the manufacture of a medicament for the prevention or amelioration of intestinal epithelial barrier damage.
Preferably, the intestinal epithelial barrier injury is a colonic epithelial barrier injury.
In a second aspect, the invention provides the use of an OPO structured lipid for the manufacture of a health product for preventing or ameliorating intestinal epithelial barrier damage.
Preferably, the intestinal epithelial barrier injury is a colonic epithelial barrier injury.
In a third aspect the present invention provides the use of an OPO structured lipid for the preparation of a functional food product for preventing or ameliorating intestinal epithelial barrier damage.
Preferably, the intestinal epithelial barrier injury is a colonic epithelial barrier injury.
Preferably, the functional food is a dairy product.
More preferably, the dairy product is milk powder.
Further preferably, the milk powder is infant milk powder.
In a fourth aspect, the present invention provides the use of an OPO structured lipid in the manufacture of a medicament, a health product or a functional food having an efficacy selected from one or more of (1) promoting proliferation of intestinal stem progenitor cells and secretion of goblet cell mucins, (2) increasing expression of claudins and (3) inhibiting apoptosis of colonic epithelial cells.
Preferably, the present invention provides the use of an OPO struct lipid for the preparation of a medicament, a health product or a functional food having at the same time the effects of (1) promoting proliferation of intestinal stem progenitor cells and secretion of goblet cell mucins, (2) increasing expression of claudins and (3) inhibiting apoptosis of colon epithelial cells.
Preferably, the tight junction protein is selected from one or more of the group consisting of ZO-1 protein, occludin protein, and Claudin-1 protein.
Preferably, the increasing the expression of the Claudin increases the expression of the Claudin-1, claudin-1 and Claudin-1 simultaneously.
Preferably, the functional food is a dairy product.
More preferably, the dairy product is milk powder.
Further preferably, the milk powder is infant milk powder.
The invention has the technical effects that:
The invention surprisingly discovers that OPO structural fat has the effect of improving the damage of the colon epithelial barrier, can improve the damage of the colon epithelial barrier by promoting the proliferation of intestinal stem progenitor cells and the secretion of mucin of goblet cells, increasing the expression of ZO-1, occludin and Claudin-1 proteins and inhibiting the apoptosis of colon epithelial cells, and can play a protective role at the low dose of 400 mg/kg.
Drawings
FIG. 1 is a schematic diagram of the experimental dosing regimen of an animal of test example 1;
FIG. 2 is a graph of OPO structural lipid relief DSS induced mice showing the results of a test for symptoms of colonic epithelial barrier injury, wherein FIG. 2A is percent weight change, FIG. 2B is colon length, FIG. 2C is disease activity index, and FIG. 2D colon tissue H & E staining;
FIG. 3 is a graph showing the results of an OPO structural lipid improvement intestinal epithelial barrier injury test, wherein FIG. 3A shows the results of OPO structural lipid promotion of intestinal stem progenitor cell proliferation; FIG. 3B shows the results of OPO structural lipid-promoted expression of goblet cell MUC 2; FIG. 3C shows the apoptosis results of OPO structural lipid inhibition colon epithelial cells;
FIG. 4 shows the results of an OPO structural lipid-enhanced colon tight junction protein expression test, wherein FIG. 4A shows ZO-1 protein expression level results, FIG. 4B shows Occludin protein expression level results, and FIG. 4C shows Claudin-1 protein expression level results.
Detailed Description
Test example 1 action of OPO structural lipid improvement model on intestinal epithelial Barrier injury in mice
1. Test method
The animal experiment design diagram is shown in figure 1. 7 week old C57BL/6J male mice were acclimatized in SPF barrier facilities for one week, given free drinking water and adequate diet. Mice were randomly divided into 4 groups of 10 mice each. The control group and the model group were respectively perfused with 0.5% sodium carboxymethylcellulose solution (0.5% CMC-Na), the low-dose OPO group was perfused with 400mg/kg, and the high-dose OPO group was perfused with 800mg/kg, until the end of the experiment. After 7 days of gastric lavage, the control group is fed with drinking water without dextran sodium sulfate (DSS, molecular weight: 36000-50000 Da); the model group and OPO treatment group were fed with 3% dss drinking water to induce a mice intestinal barrier injury model. On day 5 of modeling, 3% dss in the drinking water was removed, and normal drinking water was used instead for 3 days, and mice were sacrificed by cervical scission. During the molding process, mice were measured daily for weight change and fecal occult blood.
The specific measurement indexes and the method are as follows:
(1) Weight change: the weight of the mice was weighed using an electronic balance, and the percentage change in weight was calculated.
(2) Fecal occult blood: the fecal occult blood kit is used for measurement.
(3) Disease activity index: evaluation scores were made from three aspects of percent weight loss, fecal viscosity, fecal occult blood.
(4) Colon length: the colon segment of the mouse was removed and the length was measured with a ruler.
(5) Histopathological scoring: the colon tissue of the mice is subjected to H & E staining, the morphology of the colon tissue is observed by a microscope, and the damage degree such as the morphology of epithelial cells, the crypt structure, the thickness of mucous membrane and the like is scored.
(6) Tight junction protein expression: immunohistochemical staining method to determine ZO-1, occludin, claudin-1 protein expression level.
(7) Intestinal stem progenitor cell proliferation: immunohistochemical staining method to determine Ki67 protein expression levels.
(8) Goblet cell differentiation: immunohistochemical staining method to determine MUC2 protein expression levels.
(9) Apoptosis of intestinal epithelial cells: TUNEL staining method.
2. Test results
As shown in fig. 2, mice with DSS-induced colon barrier injury model had significantly reduced body weight, significantly shortened colon length, and significantly increased disease activity index. H & E staining showed that colon pathology such as crypt loss and tissue destruction occurred in the colon of mice in the DSS model group. The high-dose OPO group (HOPO: 800 mg/kg) and the low-dose OPO group (LOPO: 400 mg/kg) can delay the weight reduction of the colon barrier injury model mice, reduce the disease activity index, increase the colon length and improve the pathological injury of colon tissues.
The integrity of the intestinal epithelial barrier is dependent on the proliferation, differentiation and expression of the tight junction proteins of the intestinal stem progenitor cells. As shown in fig. 3 and 4, DSS treated mice had significantly reduced levels of intestinal stem progenitor cell proliferation (Ki 67 protein expression) and differentiation (MUC 2 protein expression), significantly increased levels of apoptosis, and significantly reduced expression of claudin. The OPO can promote the proliferation of intestinal stem progenitor cells and the secretion of mucin by goblet cells, inhibit the apoptosis of colon epithelial cells, increase the expression of the zonula occludens ZO-1, occludin and Claudin-1 proteins, and improve the damage of colon epithelial barriers. The test results show that the OPO structural grease has the effect of maintaining the integrity of the intestinal epithelial barrier and has the effect of obviously preventing or improving the damage of the intestinal epithelial barrier, and the OPO structural grease can be used as an active ingredient in medicines, health-care products or functional foods to play a role in the field of preventing or improving the damage of the intestinal epithelial barrier.
Although specific embodiments of the invention have been described, those skilled in the art will recognize that many changes and modifications may be made thereto without departing from the scope or spirit of the invention. Accordingly, the present invention is intended to embrace all such alterations and modifications that fall within the scope of the appended claims and equivalents thereof.
Claims (10)
- Use of an opo structured lipid for the preparation of a medicament for preventing or ameliorating intestinal epithelial barrier damage.
- 2. The use according to claim 1, wherein the intestinal epithelial barrier injury is a colonic epithelial barrier injury.
- Application of OPO structural fat in preparing health care products for preventing or improving intestinal epithelial barrier injury.
- 4. The use according to claim 3, wherein the intestinal epithelial barrier injury is a colonic epithelial barrier injury.
- Use of opo structured lipid for the preparation of a functional food for preventing or ameliorating intestinal epithelial barrier damage.
- 6. The use according to claim 5, wherein the intestinal epithelial barrier injury is a colonic epithelial barrier injury.
- 7. The use according to claim 5 or 6, wherein the functional food is a dairy product.
- 8. The use according to claim 7, wherein the dairy product is milk powder.
- Use of an opo struct fat for the preparation of a medicament, a health product or a functional food having an efficacy selected from one or more of (1) promoting proliferation of intestinal stem progenitor cells and secretion of goblet cell mucins, (2) increasing expression of claudins and (3) inhibiting apoptosis of colonic epithelial cells.
- 10. The use according to claim 9, wherein the tight junction protein is selected from one or more of the group consisting of ZO-1 protein, occludin protein and Claudin-1 protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410500133.9A CN118340760A (en) | 2024-04-24 | 2024-04-24 | OPO structural fat for preventing or improving intestinal epithelial barrier injury and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410500133.9A CN118340760A (en) | 2024-04-24 | 2024-04-24 | OPO structural fat for preventing or improving intestinal epithelial barrier injury and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118340760A true CN118340760A (en) | 2024-07-16 |
Family
ID=91822370
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410500133.9A Pending CN118340760A (en) | 2024-04-24 | 2024-04-24 | OPO structural fat for preventing or improving intestinal epithelial barrier injury and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118340760A (en) |
-
2024
- 2024-04-24 CN CN202410500133.9A patent/CN118340760A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1078079C (en) | Process for preparing Chinese medicine 'Qianjin tablets' for treating gynopathy | |
| WO2021135798A1 (en) | Application of mulberroside a and derivatives thereof in preparation of drugs for protecting intestinal barrier | |
| CN118021821A (en) | Medicine for treating and preventing related diseases caused by virus infection and application thereof | |
| CN1927322A (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN112755035A (en) | Application of tauroursodeoxycholic acid in treatment of neonatal necrotizing enterocolitis | |
| CN105213321B (en) | A kind of medicinal-bathing particle agent and application thereof of qinghaosu or derivatives thereof | |
| CN118340760A (en) | OPO structural fat for preventing or improving intestinal epithelial barrier injury and application thereof | |
| CN115869293A (en) | Application of sulforaphane to preparation of medicine for treating rheumatoid arthritis | |
| CN111920943B (en) | Application of bacillus subtilis plasmin in medicine for treating chronic prostatitis | |
| CN112891416B (en) | A Chinese medicinal composition for treating psoriasis | |
| CN114522183A (en) | Sea cucumber extract for increasing bone mineral density | |
| CN106902273A (en) | Prevent and treat pharmaceutical composition, eczema ointment of infant eczema and preparation method thereof | |
| CN103585580B (en) | A kind of Chinese medicine preparation for recurrent oral ulceration | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| CN113559189A (en) | Traditional Chinese medicine composition for treating dermatitis or eczema | |
| CN111249381A (en) | Application of composition in preparation of medicine for preventing and treating constipation | |
| CN110893202A (en) | Medicinal liquor for treating gout | |
| CN112516158B (en) | Composition for treating pharyngitis and preparation method thereof | |
| CN110652009B (en) | New use of high fiber dietary supplement for preventing and improving bone metabolism related diseases | |
| CN112438991B (en) | Medical application of heparin, or derivative thereof, or pharmaceutically acceptable salt thereof | |
| CN113425713B (en) | Pharmaceutical composition for treating duodenal ulcer | |
| CN115998788B (en) | Application of luffa alcohol precipitation extract for treating allergic rhinitis | |
| CN102302702B (en) | Medicament for treating infantile diarrhea | |
| US20240009250A1 (en) | Therapeutic application of cell-free fat extract to arthritis | |
| CN117883452A (en) | Application of lupeone in preparation of product for preventing and treating intestinal mucosa injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |